Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer
(Thomson Reuters ONE) -
DUBLIN, Ireland, June 12, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc
(NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the
discovery, development and commercialization of novel protein immunotherapies,
announced today the appointment of Wagner Zago, PhD, as Chief Scientific Officer
(CSO). Dr. Zago, who has been Prothena's Head of Research since 2015, will have
responsibility for defining and executing the company's research strategy and
advancing the company's drug discovery pipeline.
"Wagner is a prolific and talented scientist whose expertise has been central to
Prothena's ability to build a diverse pipeline of internally discovered first-
in-class therapies," stated Gene Kinney, PhD, President and Chief Executive
Officer of Prothena. "His appointment to the position of CSO reflects our deeply
held commitment to our scientific roots and the continued discovery of novel
therapies based on our expertise in protein misfolding and cell adhesion. Beyond
his exceptional and widely respected scientific talent, Wagner brings tremendous
leadership and strategic planning capabilities to our management team that will
advance our capacity to develop innovative medicines."
Dr. Zago joined Prothena in 2012 when the company was founded after spinning out
of Elan Pharmaceuticals, first as Head of Pharmacology and Neuropathology and
more recently as Vice President, Head of Research. During his tenure at
Prothena, he has led teams that have built a strong discovery pipeline and
advanced four programs based on novel mechanisms through discovery and
preclinical development into the clinic. Dr. Zago holds several key patents and
has published broadly in the areas of protein immunotherapy and central nervous
system (CNS) disorders. Before Prothena, he was Principal Scientist at Elan
Pharmaceuticals performing research aimed at developing new therapeutics for CNS
disorders, including beta amyloid-targeted therapies and supportive research for
the development of natalizumab, which was commercialized by Biogen for relapsing
multiple sclerosis. While in this position he also served as a Scientist at
Janssen Alzheimer Immunotherapy, where he made significant discoveries about
vascular changes associated with anti-beta amyloid immunotherapy. Previously, he
was a Postdoctoral Researcher at the University of California - San Diego and
the Burnham Institute. Dr. Zago received his PhD in Pharmacology at the
Universidade de Sao Paulo, Brazil.
About Prothena
Prothena Corporation plc is a global, late-stage clinical biotechnology company
establishing fully-integrated research, development and commercial capabilities.
Fueled by its deep scientific understanding built over decades of research in
protein misfolding and cell adhesion - the root causes of many serious or
currently untreatable amyloid and inflammatory diseases - Prothena seeks to
fundamentally change the course of progressive diseases associated with this
biology. The Company's pipeline of antibody therapeutic candidates targets a
number of indications including AL amyloidosis (NEOD001), Parkinson's disease
and other related synucleinopathies (PRX002/RG7935), inflammatory diseases,
including psoriasis and psoriatic arthritis (PRX003), and ATTR amyloidosis
(PRX004). The Company continues discovery of additional novel therapeutic
candidates where its deep scientific understanding of disease pathology can be
leveraged. For more information, please visit the Company's website
at www.prothena.com
Media & Investor Contact:
Ellen Rose, Head of Communications
650-922-2405, ellen.rose(at)prothena.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Prothena Corporation plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 12.06.2017 - 15:00 Uhr
Sprache: Deutsch
News-ID 547409
Anzahl Zeichen: 4540
contact information:
Town:
DUBLIN
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 251 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer"
steht unter der journalistisch-redaktionellen Verantwortung von
Prothena Corporation plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
